NewLimit
NewLimit is a biotechnology company focused on extending human healthspan by developing epigenetic reprogramming medicines for age-related diseases. They utilize functional genomics, machine learning, and innovative experimental methods to understand and treat biological aging.
Headquarters
South San Francisco, California, United States
Company Size
11-50 employees
Founded
2022
NewLimit is a biotechnology company focused on extending human healthspan by unlocking regenerative potential. It builds therapies and platform technologies aimed at restoring youthful function to tissues and organs by targeting core cellular and molecular drivers of aging. NewLimit advances programs through preclinical research and collaborations to translate regenerative biology into treatments for age‑related disease. The company emphasizes translational science with the goal of delivering durable, clinically meaningful rejuvenation across organ systems.
Anti-aging biotech NewLimit brings in Eli Lilly as investor, raising $45M
Oct 20, 2025
Anti-aging biotech NewLimit raises $130M to push liver reprogramming med into clinic
May 6, 2025
NewLimit ‘close’ to clinic-ready epigenetic reprogramming therapy
Nov 27, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for NewLimit.
NewLimit Raises $45 Million Funding to Advance Longevity Research
Oct 21, 2025
Postdoctoral Associate
The Jackson Laboratory
Scientist II, Cellular Immunology
AbbVie
Scientist, Genomics
Retro Biosciences
Cell Biology R&D Co-op
Leica Biosystems
Postdoctoral position in single-cell functional genomics, Norman Lab
Memorial Sloan Kettering Cancer Center
Postdoctoral Position in the Cancer Epigenetics Group
UMB Bank